story of the week
ADT With and Without Docetaxel and Estramustine for High-Risk Localized Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Early Docetaxel in New Metastatic Hormone Sensitive Prostate Cancer: Why CHAARTED and STAMPEDE Showed What GETUG Could Not
- Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer
- Treatment of the Primary Tumor in Metastatic Prostate Cancer
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Androgen Deprivation Therapy Plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-Risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial
Lancet Oncol 2015 May 28;[EPub Ahead of Print], K Fizazi, L Faivre, F Lesaunier, R Delva, G Gravis, F Rolland, F Priou, JM Ferrero, N Houede, L Mourey, C Theodore, I Krakowski, JF Berdah, M Baciuchka, B Laguerre, A Fléchon, A Ravaud, I Cojean-Zelek, S Oudard, JL Labourey, P Chinet-Charrot, E Legouffe, JL Lagrange, C Linassier, G Deplanque, P Beuzeboc, JL Davin, AL Martin, M Habibian, A Laplanche, S CulineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.